SciSparc Ltd. (NASDAQ:SPRC) Short Interest Down 56.2% in January

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 176,031 shares, a decrease of 56.2% from the January 15th total of 401,983 shares. Approximately 5.0% of the shares of the stock are sold short. Based on an average trading volume of 562,920 shares, the days-to-cover ratio is presently 0.3 days. Based on an average trading volume of 562,920 shares, the days-to-cover ratio is presently 0.3 days. Approximately 5.0% of the shares of the stock are sold short.

SciSparc Stock Up 2.0%

Shares of NASDAQ SPRC traded up $0.01 during mid-day trading on Thursday, reaching $0.63. The company had a trading volume of 14,533 shares, compared to its average volume of 1,728,012. The business’s 50-day simple moving average is $1.27 and its 200 day simple moving average is $2.88. SciSparc has a one year low of $0.58 and a one year high of $11.51.

SciSparc (NASDAQ:SPRC) last announced its quarterly earnings data on Tuesday, November 18th. The company reported ($3.08) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.